RxDoctor Payments Data

Alina Sanda, MD

Internal Medicine · Baltimore, MDNPI 1982887683

Payments from drug & device makers

$2,254in general payments, 2019–2025

Across 118 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$449
  • Lilly USA, LLC$448
  • Novo Nordisk$357
  • GSK$204
  • Boehringer Ingelheim$135
  • Sanofi-aventis U.S. LLC$120
  • plus $541 from 16 others

What the payments were for

  • Food & beverage$2,254100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,254 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$59,695
Medicare patients
89
Services billed
701

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$89,926
JardianceEmpagliflozin19$24,609
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$20,030
EliquisApixaban15$16,446
FarxigaDapagliflozin Propanediol11$14,584
Repatha SureclickEvolocumab13$8,046
Rosuvastatin Calcium138$4,811
Breo ElliptaFluticasone/Vilanterol11$4,108
Albuterol Sulfate HfaAlbuterol Sulfate106$4,091
Pravastatin Sodium94$2,565
Diclofenac Sodium36$2,358
Atorvastatin Calcium87$1,997
Amlodipine Besylate175$1,872
Losartan Potassium115$1,704
Metoprolol Succinate87$1,638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$357$89,92648 claims
Boehringer IngelheimJardiance$135$24,60919 claims
GSKTrelegy Ellipta, Breo Ellipta$204$24,13832 claims
PfizerEliquis$21$16,44615 claims
AstraZenecaFarxiga$449$14,58411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →